Results 31 to 40 of about 6,658 (202)

Evaluation of Drug–Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor

Clinical and Translational Science, 2019
This phase I study (CO‐338‐044; NCT02740712), conducted in patients with advanced solid tumors, evaluated the effect of the poly(ADP‐ribose) polymerase (PARP) inhibitor rucaparib on the pharmacokinetics (PK) of caffeine 200 mg, warfarin 10 mg, omeprazole
Jim J. Xiao, Dorota Nowak, Rodryg Ramlau, Monika Tomaszewska‐Kiecana, Piotr J. Wysocki, Jeff Isaacson, Jeri Beltman, Eileen Nash, Robert Kaczanowski, Gerhard Arold, Simon Watkins   +10 more
doaj   +1 more source

What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib

Frontiers in Oncology, 2022
BackgroundThe poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib was approved in the United States based on the phase 2 TRITON2 study of patients with BRCA1 or BRCA2 (BRCA)–mutated metastatic castration-resistant prostate cancer (mCRPC).
Daniel P. Petrylak, Simon P. Watkins, Andrea Loehr   +2 more
doaj   +1 more source

Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10Research in context

EBioMedicine, 2023
Summary: Background: PARP inhibitors (PARPi) have revolutionized the management of advanced ovarian carcinoma, and were investigated as forefront treatment in recurrent disease.
Olivier Colomban, Elizabeth M. Swisher, Rebecca Kristeleit, Iain McNeish, Ronnie Shapira-Frommer, Sandra Goble, Kevin K. Lin, Lara Maloney, Gilles Freyer, Benoit You   +9 more
doaj   +1 more source

Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10 [PDF]

, 2020
Treatment options for women with recurrent ovarian cancer who have received two or more prior lines of chemotherapy have recently expanded with the U.S.
Kristeleit, RS, Ray-Coquard, I, Drew, Y, Oaknin, A, Haris, NM, Swisher, EM   +5 more
core   +1 more source

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?

Medicines, 2020
Poly adenosine diphosphate-ribose polymerase inhibitors (PARPi) represent an effective therapeutic strategy for cancer patients harboring germline and somatic aberrations in DNA damage repair (DDR) genes.
Angela Dalia Ricci, Alessandro Rizzo, Chiara Bonucci, Nastassja Tober, Andrea Palloni, Veronica Mollica, Ilaria Maggio, Marzia Deserti, Simona Tavolari, Giovanni Brandi   +9 more
doaj   +1 more source

Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis

Frontiers in Oncology, 2021
This meta-analysis investigated the comparative efficacy and safety of PARP inhibitor monotherapy as maintenance treatment in platinum sensitive recurrent ovarian cancer (ROC). Electronic databases were systematically searched for relevant RCTs.
Yangchun Xu, Lei Ding, Yuan Tian, Miaomiao Bi, Ning Han, Ling Wang   +5 more
doaj   +1 more source

Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile [PDF]

, 2021
Background: Targeted agents, such as antiangiogenic drugs (e.g., bevacizumab) and poly(ADP-ribose) polymerase inhibitors (e.g., rucaparib), have been shown to improve outcomes in patients with newly diagnosed or recurrent ovarian cancer.
Ceruti T., Cresta S., Matteo C., Sabatucci I., D'Incalci M., Raspagliesi F., de Braud F., Sonetto C., Giolitto S., Sinno V., Ronzulli D., Lorusso D., Zucchetti M., Maltese G.   +13 more
core   +1 more source

Advances in the use of PARP inhibitor therapy for breast cancer

Drugs in Context, 2018
Poly-ADP-ribose polymerase 1 (PARP-1) and PARP-2 are DNA damage sensors that are most active during S-phase of the cell cycle and that have wider-reaching roles in DNA repair than originally described.
Kelly E McCann, Sara A Hurvitz
doaj   +1 more source

Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting

Therapeutic Advances in Medical Oncology, 2020
The use of targeted therapeutics known as poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the management of ovarian cancer is currently transforming clinical practice. The PARP inhibitor rucaparib is indicated in the UK, European Union
Laura Tookman, Jonathan Krell, Baleseng Nkolobe, Laura Burley, Iain A. McNeish   +4 more
doaj   +1 more source

Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS

Frontiers in Pharmacology, 2022
Background: Several poly ADP ribose polymerase inhibitors (PARPis) are currently approved for the treatment of a variety of cancers. The safety profile of PARPis has not yet been systemically analyzed in the real world.
Xiaojiang Tian, Lin Chen, Di Gai, Sijie He, Xuan Jiang, Ni Zhang   +5 more
doaj   +1 more source